Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director | September 09, 2026 | September 10, 2026 |
| Larimar Therapeutics, Inc.LRMR · Entity 5634 | Director | May 19, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date September 09, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-09-09 | Direct | 148,000 |
Reported balance
After 2026-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-09 · Grant · Acquired 148,000 · Balance 148,000 F1: Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan.
Larimar Therapeutics, Inc.
Report date May 19, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2036-05-19 | Direct | 55,150 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 55,150 · Balance 55,150 F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 3,500 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2026-01-20 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 142,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.59 · Expires 2021-12-12 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-28 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-28 · Disposition to issuer · Disposed 185,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.78 · Expires 2028-05-01 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-28 · Disposition to issuer · Disposed 632,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2024-03-04 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2020-12-16 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-01-28 · Disposition to issuer · Disposed 87,766 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2023-12-17 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-01-28 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-01-28 · Disposition to issuer · Disposed 419,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-01-28 · Disposition to issuer · Disposed 1,097,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
BIOSPECIFICS TECHNOLOGIES CORP
Report date December 02, 2020 · Filed December 02, 2020
Section 16 reporting ended · disclosed 2020-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.72 · Expires 2030-05-28 | Direct | 0 |
Reported balance
After 2020-12-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-02 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (May 28, 2020), were canceled in exchange for a cash payment of $2,478,000.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (May 28, 2020), were canceled in exchange for a cash payment of $2,478,000.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 10, 2026 21:48 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 148,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001452429-26-000005 · form4-09102026_090949.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2036-09-09 F1 · derivative.exercise_date: Century Therapeutics, Inc. (the "Company") issued to the Reporting Person stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to the Reporting Person's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:28 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 55,150 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001193125-26-232667 · ownership.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,150 Underlying: Common Stock · 55,150 shares Expires 2036-05-19 F1 · derivative.exercise_date: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| May 13, 2025 Filed May 14, 2025 20:33 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001062993-25-009379 · form4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-05-13 F1 · derivative.exercise_date: The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:57 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001062993-24-011569 · form4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| May 17, 2023 Filed May 18, 2023 18:12 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | PurchaseCommon Stock | 2,750 | $3.73 | $10,257.50 |
DisclosureSEC source: 0001062993-23-011545 · form4.xml · nonDerivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:29 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 8,300 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001062993-23-010808 · form4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2033-05-09 F1 · derivative.exercise_date: The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:28 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 8,300 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001062993-22-012307 · form4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2032-05-10 F1 · derivative.exercise_date: The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| May 12, 2021 Filed May 20, 2021 12:48 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (right to buy) · Derivative | 8,300 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001192482-21-000445 · edgar.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 Underlying: Common Stock · 8,300 shares Expires 2031-05-12 F1 · derivative.exercise_date: The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 09:45 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | Disposition to issuerStock Option (Right to Buy) · Derivative | 100,000 | $24.78 Strike: $63.72 | $2,478,000.00 |
DisclosureSEC source: 0000899243-20-032451 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (May 28, 2020), were canceled in exchange for a cash payment of $2,478,000.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 18:00 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (right to buy) · Derivative | 16,600 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001192482-20-000742 · edgar.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Underlying: Common Stock · 16,600 shares Expires 2030-07-16 F1 · derivative.exercise_date: The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The vesting commencement date for the option is July 16, 2020, and the option vests in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. Read SEC document |
| May 28, 2020 Filed May 29, 2020 14:32 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $63.72 | $0.00 |
DisclosureSEC source: 0000899243-20-014517 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2030-05-28 F1 · kind: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. F2 · derivative.exercise_date: The stock options vest in four equal installments over the four-year period following the date of grant. Read SEC document |
| May 28, 2020 Filed Oct 19, 2020 16:15 UTC Amendment | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $63.72 | $0.00 |
DisclosureSEC source: 0000899243-20-028608 · doc4a.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-05-28 F1 · kind: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan (the "Plan"). F2 · shares: As previously reported on a Form 4 filed on May 29, 2020 by the reporting person, the reporting person reported acquiring stock options to purchase 130,000 shares of common stock. However, BioSpecifics Technologies Corp. (the "Company") subsequently determined that stock options to purchase 30,000 shares of common stock under the Plan were not validly granted pursuant to the Plan because they exceeded the Plan limit on the number of stock options that may be granted to any newly-hired employee participant in any one calendar year. Accordingly, the attempted grant of these excess stock options was ineffective, and they were never granted to the reporting person. The reporting person is filing this amendment to report the correct amount of stock options acquired. F3 · derivative.exercise_date: The stock options vest in four equal installments over the four-year period following the date of grant. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 1,097,000 | Not disclosed Strike: $2.18 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 10 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,097,000 shares Expires 2029-01-23 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 419,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 9 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 419,000 shares Expires 2028-02-09 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 200,000 | Not disclosed Strike: $3.02 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 8 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2023-12-17 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 87,766 | Not disclosed Strike: $3.10 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 7 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,766 shares Expires 2020-12-16 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $3.66 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 6 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-03-04 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 632,000 | Not disclosed Strike: $3.78 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 5 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 632,000 shares Expires 2028-05-01 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 185,000 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 4 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,000 shares Expires 2027-01-17 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 100,000 | Not disclosed Strike: $7.59 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 3 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-12-12 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 142,000 | Not disclosed Strike: $7.61 | Not disclosed |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · derivative · entry 2 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 142,000 shares Expires 2026-01-20 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:15 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerCommon Stock | 3,500 | $6.30 | $22,050.00 |
DisclosureSEC source: 0001562180-20-000676 · primarydocument.xml · nonDerivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,234 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · derivative · entry 6 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,766 Underlying: Common Stock · 100,234 shares Expires 2020-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on December 16, 2010 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Exercise / conversionStock Option (Right to Buy) · Derivative | 33,250 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · derivative · entry 5 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,250 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | SaleCommon Stock | 33,250 | $6.37 | $211,965.43 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · nonDerivative · entry 4 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | SaleCommon Stock | 100,234 | $6.37 | $638,981.73 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · nonDerivative · entry 3 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,750 Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Exercise / conversionCommon Stock | 33,250 | $3.28 | $109,060.00 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · nonDerivative · entry 2 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Exercise / conversionCommon Stock | 100,234 | $3.10 | $310,725.40 |
DisclosureSEC source: 0001562180-19-005195 · primarydocument.xml · nonDerivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:50 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantStock Option (Right to buy) · Derivative | 1,097,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-19-005373 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,000 Underlying: Common Stock · 1,097,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| May 01, 2018 Filed May 3, 2018 16:59 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 632,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001209191-18-027687 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,000 Underlying: Common Stock · 632,000 shares Expires 2028-05-01 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 17:21 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 419,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-009670 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,000 Underlying: Common Stock · 419,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:23 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 185,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-17-004611 · doc4.xml · derivative · entry 1 Truitt Joseph · CIK 0001452429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-01-17 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period following the first anniversary of the grant date until the fourth anniversary of the grant date. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 17:18 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | PurchaseCommon Stock | 3,500 | $4.06 | $14,210.00 |
DisclosureSEC source: 0001209191-16-153426 · doc4.xml · nonDerivative · entry 1 Truitt Joseph · CIK 0001452429 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.